Al Kindy College of Medicine/ University of Baghdad
Baghdad, 10096, Iraq
NCT Number: NCT03755531
Postpartum haemorrhage keeps to be the leading cause of maternal mortality in middle and low-income countries, including Iraq. Much advancement had been made in the field of treatment for postpartum haemorrhage but no much progress had been made in the field of prevention, where one of its main component is the administration of uterotonic, preferably oxytocin, immediately after birth of the baby.
In many low- and middle income countries, the efficacy of oxytocin cannot be assured since access to sustained cold-chain is unavailable. Regarding the other uterotonics; ergometrine degrades when exposed to heat or light. Misoprostol degrades rapidly when exposed to Moisture.
Innovation in the manufacture of carbetocin had meet the stability requirements for hot and humid climates.
This study had been accomplished to evaluate the uterotonic effect of carbetocin compared with oxytocin for the prevention of postpartum haemorrhage in emergency caesarean delivery. Looking if carbetocin is superior to oxytocin in term of reduction in the need for additional uterotonic agents or the occurrence of PPH.
Looking for future studies?
Notify Me18 year–43 year
Female
Interventional
Phase 4
Baghdad, 10096, Iraq
Setting and design:
It is a double blinded randomized parallel clinical trial. That had been conducted at Al Elweyia Maternity Teaching Hospital in Baghdad during the period from Jan., 4th, 2018 to August, 1st, 2018. Written consent was insured for all the participants.
Data collection:
Three hundred and twenty pregnant women who were underwent emergency caesarean sections under regional anesthesia were enrolled in the study (due to limitation of carbetocin ampoules that were available). Those women were randomized to oxytocin or carbetocin in a rate of 2:1 (for prophylaxis of PPH in the active management of third stage of labour). Twenty cases were omitted since they were not fulfilled the eligibility criteria and only three hundred women were completed the study. They were divided into two groups:
Group1 (case group): 100 pregnant women, whom they received carbetocin for the prevention of PPH.
Group 2 (control group): 200 pregnant women, whom they received oxytocin for the prevention of PPH.
Additional information including age, parity, past medical history, and body mass index (BMI) were taken.
Intervention:
The following steps were followed:
Follow up:
For 24 hours was done, that is include:
Statistical analysis:
Statistical Package for Social Sciences (SPSS) version 21 was used. Descriptive statistics presented as (mean ± standard deviation) and frequencies as percentages. The database was examined for errors using range and logical data cleaning methods, and inconsistencies were remedied. Chi square test was used to compare between categorical variables (Fishers exact test used when expected variable was less than 20% of total) and t-test was used to compare between two means. Cohen's d, a standardized measure of effect size for difference between 2 means, which can be compared across different variables and studies, since it has no unit of measurement was used. Significance level was set at P < 0.05.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.
Drug was kept in cold storage (2 to 8°C).
Other names: BABAL
Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.
Drug was kept in cold storage (2 to 8°C).
Other names: Pitocin
Time frame: During the first 24 hours
Proportion of women with blood loss equal or more than 1000 ml in both study groups
Time frame: During the first 24 hours
Proportion of the women whom they need additional uterotonic agents
Time frame: Within one hour after administration of the drugs
Systolic and diastolic blood pressure changes that may occur in both groups
Time frame: Within one hour after administration of the drugs
Detection of pulse rate changes that may occur in both groups
Time frame: During the first 24 hours
Proportion of the women whom they need blood transfusion
Al-Kindy College of Medicine
Other
Heat Stable Carbetocin Versus Oxytocin for the Prevention of Primary Postpartum Hemorrhage in Emergency Caesarean Delivery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07713277
Delayed Cord Clamping, Female Urogenital Diseases and Pregnancy Complications
Vicenza, Italy
View Trial DetailsNCT07019623
Balloon, Cesarean Delivery
Zurich, Switzerland
View Trial DetailsNCT07187544
Female Urogenital Diseases and Pregnancy Complications, Hemorrhage
Toronto, Ontario, Canada
View Trial DetailsNCT06646653
Familial Primary Pulmonary Hypertension, Female Urogenital Diseases and Pregnancy Complications
Brooklyn, New York, United States
View Trial Details